In this study, we analyzed the Norwegian guidelines for systematic follow-up after curative colorectal cancer surgery in a large single institution. Three hundred fourteen consecutive unselected patients undergoing curative surgery for colorectal cancer between 1996 and 1999 were studied with regard to asymptomatic curable recurrence, compliance with the program, and cost. Follow-up included carcinoembryonic antigen (CEA) interval measurements, colonoscopy, ultrasonography of the liver, and radiography of the chest. In 194 (62%) of the patients, follow-up was conducted according to the Norwegian guidelines. Twenty-one patients (11%) were operated on for curable recurrence, and 18 patients (9%) were disease free after curative surgery for recurrence at evaluation. Four metachronous tumors (2%) were found. CEA interval measurement had to be made most frequently (534 tests needed) to detect one asymptomatic curable recurrence. Follow-up program did not influence cancer-specific survival. Overall compliance with the surveillance program was 66%, being lowest for colonoscopy (55%) and highest for ultrasonography of the liver (85%). The total program cost was V 228,117 (US $ 280,994), translating into V 20,530 (US $ 25,289) for one surviving patient after surgery for recurrence. The total diagnosis yield with regard to disease-free survival after surgery for recurrence was 9%. Compliance was moderate. Whether the continuing implementation of such program and cost are justified should be debated. ( J GASTROINTEST SURG 2005;9:320-328) Ć
Colorectal cancer (CRC) is the second most common malignant disease, affecting both sexes in a worldwide perspective. [1] [2] [3] Recurrence after curative resection is reported in 30-50% of the patients and causes considerable morbidity and mortality. [4] [5] [6] Systematic postoperative surveillance after curative surgery for CRC has been applied widely. Early detection of recurrence has been regarded as important to enable curative surgical treatment of localized hepatic or pulmonary metastases in selected patients. [7] [8] [9] [10] Although the effectiveness of such programs has been questioned, 11, 12 two recent reviews have provided some support to the evidence that systematic follow-up of these patients does have a beneficial effect on survival. 13, 14 In Norway, national guidelines were established in the 1990s by the Norwegian Gastro-Intestinal Cancer Group (NGICG) with a focus on both intraluminal recurrence and distant spread 15, 16 (Table 1 ). The cost-effectiveness of these guidelines was shown in a model. 17 However, little is known about the real yield of this program and compliance with the recommendations, and the cost of its implementation had not been accurately determined. The need for Carcinoembryonic antigen
cost identification of follow-up programs has been expressed by some authors. 13 The objective of this study was to evaluate the effectiveness of the Norwegian guidelines for follow-up after curative surgery for CRC in a population-based patient cohort in terms of asymptomatic resectable recurrent disease, compliance with guidelines, and cost.
PATIENTS AND METHODS
All patients with a diagnosis of adenocarcinoma of the colon and rectum seen at our institution between July 1996 and June 1999 were included in the study. Our institution provides regional surgical and oncologic care for a population of 280,000. Surgical treatment was performed according to general recommendations, including total mesorectal excision (TME) in rectal cancer with preoperative radiation therapy in selected cases. 16, 18 Patients younger than 76 years of age with stadium Dukes C colon cancer were offered postoperative adjuvant chemotherapy for 6 months (5-fluorouracil/leucovorin).
Follow-up
All curatively treated patients 75 years old or younger had follow-up according to the NGICG guidelines (Table 1) , 16 whereas older patients were not followed routinely. Modifications of this schedule were made in some cases mainly according to the wishes of the patients, and in rare cases by the responsible surgeon.
Data Collection
Patients with CRC were identified from hospital data using ICD-9 codes 153 and 154; in addition, data from the Department of Pathology. Histology for all patients were reviewed. The hospital records of the identified 441 patients were evaluated. Date of death was obtained from the electronic patient record system of our hospital, which is directly linked via a unique 11-digit personal identification number to the government Public Registry of inhabitants. Cause of death was verified by a review of patient records or, in a few cases, from various sources, including patients' general practitioners or convalescent houses. The ASA classification was used to express the state of health. 19 All postoperative examinations were reviewed. Carcinoembryonic antigen (CEA) values were registered preoperatively and postoperatively, as well as in the case of local recurrence and/or distant spread. Recurrence at the site of primary tumor and distant spread were registered, based on clinical findings, imaging studies, and/or histologic diagnosis. Treatment of relapse was recorded with regard to type of treatment (curative versus palliative). Cause of death was recorded and categorized in each case. The diagnostic modality establishing recurrent disease was recorded.
Definitions
Curative treatment was defined as macroscopically complete surgical resection (R0) in the absence of distant disease on preoperative ultrasonogram of the liver and radiograph of the chest and after surgical exploration of the abdominal cavity. Local recurrence was categorized as either intraluminal or extraluminal. Histologic confirmation was made when feasible. Distant metastasis was defined as evidence of a secondary tumor away from the primary location and was diagnosed clinically with imaging studies or tissue biopsy. The effectiveness of a test was defined as the ability to detect curable asymptomatic recurrent disease in all patients with systematic postoperative surveillance. Compliance with the follow-up program was defined as the proportion represented by dividing the total number of surveillance tests performed into the total number of tests scheduled according to the surveillance program.
Statistical Analysis
Data were analyzed with regard to local recurrence, distant metastases, and survival, related to patients with systematic follow-up. 
RESULTS
Four hundred forty-one patients were diagnosed with CRC during the study period, translating into an annual incidence of 52.5/100.000, or an average of 150 patients. Three hundred fourteen patients were treated with curative intention (71%; annual incidence of 37.4/100.000). Among these patients, systematic follow-up was indicated in 194 (62%; age р75 years of age) according to the NGICG guidelines ( Fig. 1 ). Patient and tumor characteristics are given in Table 2 . Median follow-up time was 66 months (range, 48-84 months). Median age as well as distribution of ASA classification was significantly different compared with the patient group with and without systematic follow-up, respectively. No differences with regard to gender or tumor characteristics were observed (Table 2) . Postoperative mortality (30 days) was 3.5% (11 patients). Crude survival was significantly better (P Ͻ 0.0001) in the follow-up group (73%) compared with the patients without follow-up (52%) (Fig. 2, A) . Cancer-specific survival, however, was similar (79% versus 86%, P ϭ 0.7) in both groups (Fig. 2, B) .
Effectiveness of Postoperative Surveillance
Details from follow-up are shown in Table 3 . From all observed recurrences, 23% were asymptomatic with curative potential, whereas 77% were either symptomatic and/or incurable. The effectiveness to detect asymptomatic resectable recurrence was 11% (21 patients) from 194 surveyed patients (Fig. 3) , whereas the overall effectiveness (resectable recurrence regardless of whether asymptomatic) was 16% (31 patients). The numbers of patients with distant spread were significantly higher in the group with systematic follow-up. The median time until diagnosis of local recurrence or distant spread, however, was similar in both groups (21 months; interquartile range, 13-30 months; Figs. 2, C and D). In the Dukes A group, six recurrences (two liver metastases, two lung metastases, two local recurrences) were seen (n ϭ 55; 11%). All had rectal cancer, whereas none of those with Dukes A colonic cancer had recurrence. In the Dukes B and C groups, recurrences were equally distributed. Local recurrences were found in 7% of the rectal cancer patients and 10% of the colon cancer patients (P ϭ 0.4). Of the patients with asymptomatic resectable disease, nine hepatic resections, five pulmonary resections, five bowel resections, and two other procedures were performed. Clinical examination revealed an additional nine patients with symptomatic recurrence, and they underwent bowel resections with curative intention. At last follow-up, 18 of 21 asymptomatic patients (86%) were still alive without evidence of disease. Accordingly, the yield of this strict surveillance program was 9% of the 194 patients. The effectiveness of the various modalities of routine examination is shown in Table 4 and was greatest for colonoscopy after 1 and 5 years, respectively, and lowest for CEA. The effectiveness of computed tomography examinations done on specific indications was 3.1%. The number of tests needed to detect one asymptomatic patient with curable disease is given in Table 4 . Numbers varied widely between the various test modalities.
Compliance With Follow-up
The overall compliance with the follow-up program was 66% (3661 of 5519 scheduled tests). Twenty-one patients (11%) older than 75 years (between 76 and 83 years of age) had been followed systematically. For various tests, compliance varied from 55% (1-year colonoscopy) to 85% (ultrasonography of the liver) ( Table 4) . Compliance with 5-year colonoscopy was calculated with regard to the 104 patients with an observation time of at least 60 months. When extrapolating the values from Table  4 , a 100% follow-up might have yielded an additional 11 patients with potentially curable recurrent disease.
Cost
The costs were calculated based on hospital charges, which are confined to the reimbursements 
DISCUSSION
The findings of our study concur well with the national statistics from the Norwegian Cancer Registry. 20 Our population-based observations should apply to the general population.
Our postoperative surveillance program had an effectiveness of 11% with regard to curable asymptomatic recurrence and increased to 16% in symptomatic patients. Nine percent of the patients with follow-up eventually received curative treatment for recurrent disease, and most remained free of disease (85%). In this select group, the benefit of surveillance is apparent. However, it is important to note that our observed figures apply to patients 75 years old or younger in whom surgery for recurrent disease may be warranted. Patients of greater age and most likely a higher frequency of comorbidity have not been followed according to a fixed schedule ( Table 1 ). The effectiveness of follow-up after curative surgery for CRC is reported to vary considerably, with a range between 2% and 20%. [21] [22] [23] [24] This depends largely on which study population is analyzed. Although some studies report on patients participating in trials for adjuvant chemotherapy, 21, 22 other focus on particular sites of recurrence. 23 Furthermore, at the present time, there is no general consensus as to which examinations and tests should be included. 13 Some studies focus on the detection of intraluminal recurrence, 25, 26 and others also include the detection of distant spread by CEA monitoring or imaging studies. 27, 28 However, the problem of postoperative cancer surveillance is that a vast majority of patientsin the present study, 89%-have to undergo a large number of tests without any benefit, or even with some harm, to identify a few patients with curable recurrence. Most patients will not have a recurrence (60%) or are diagnosed because of symptoms (19%). It has been shown that close follow-up can lead to psychological stress. 29 In a Danish randomized controlled trial, health-related quality of life was only marginally improved in patients with regular followup. 30 Patients with asymptomatic but incurable disease (9%) represent probably the most controversial group and raise serious ethical considerations. 31 Even with more effective palliative chemotherapy during the past decade, cure is seldom seen. 32, 33 Although systematic postoperative surveillance is extensively studied with regard to cure and survival, the possible Local recurrence 29 (9) 22 (76) 7 (24) benefit of surveillance with regard to a better outcome of palliative care and quality of life is, to our knowledge, not well described.
In the present study, 270 tests were needed to find one patient with recurrent disease, in whom curative surgery was achievable. Kievit 34 reported a number of 360 diagnostic efforts that was needed to achieve the same. However, a great uncertainty is related to the effectiveness of figures and costs of follow-up as expressed by the large CIs (Table 4) . We are not aware of any previous studies reporting 95% CIs as shown in our report. Our observations reflect the small gain of a strict follow-up program as expressed by low numbers of recurrences even in a large patient series undergoing thousands of examinations. The major problem of all follow-up programs for CRC is that there is, at the present time, no sufficient diagnostic tool with acceptable sensitivity and specificity to detect recurrent disease at an early stage when curative treatment is possible. Therefore, a multimodality follow-up covering the sites of highest incidence of recurrence and where effective treatment options are available is necessary. The Norwegian follow-up program with focus on hepatic, pulmonary, and intraluminal recurrences as well as metachronous tumors showed an effectiveness of 9%. For each test modality, compliance and the number of patients with asymptomatic curable disease (effectiveness) by that particular test are calculated, as well as the number of tests to be done to detect one asymptomatic curable patient. *Not part of the guidelines; computed tomography scans of liver and lungs were done when ultrasound and/or chest radiographic examination were unsatisfactory.
Our guidelines are based on CEA measurements. As the value of serial CEA measurement is still unclear, this aspect deserves further evaluation. 28, 35, 36 The evidence of the benefit of systematic surveillance was earlier characterized as inconclusive, 37 two recent meta-analyses support the attitude that postoperative surveillance is probably associated with a survival benefit. 13, 14 However, the conclusions that can be drawn from these meta-analyses seem to be limited because of serious methodologic flaws of the primary studies, like insufficient power to detect any statistically significant differences and the fact that the various follow-up programs were hard to compare. 2, 36 It has been suggested that an appropriate randomized controlled trial to address these issues would require inclusion of at least 25,000 patients. 38 However, when effective treatment of hepatic and pulmonary recurrences is available, [7] [8] [9] [10] it is questionable whether a randomized controlled trial with regard to a followup or not is feasible and ethically justifiable. Thus, the question should be not only whether surveillance should be performed but also which follow-up program should be applied and which patient group should be surveyed. Furthermore, surveillance programs should take into account whether the individual patient will be a candidate for salvage surgery for recurrence. 39, 40 Thus, it is a challenge to determine which patient groups will benefit from follow-up and what kind of program is appropriate.
The cost-effectiveness of the Norwegian guidelines was earlier found to be acceptable when applied to a model based on outcome figures from the literature. 17 This study suggested a recurrence rate of 40% with a median recurrence time of 10 months and a 10% rate of curative surgery. Figures from our study are in accordance with the earlier reported results. However, time to relapse was in our study twice as long as suggested in this analysis. The assumptions made by Norum and Olsen 17 are based on patients treated between 1971 and 1991, before the concept of TME was widely implemented, and local recurrences rates of 20-30% were reported, which often occurred within the first 18 months after surgery. 41, 42 Since 1994, the TME technique is used routinely in the treatment of rectal cancer in Norway. 16, 43 The follow-up program used at our department adhered almost completely to the Norwegian guidelines. Both CEA measurement and ultrasound imaging of the liver were offered independently of preoperative CEA values. This program was prolonged from 4 to 5 years. The overall compliance was 66%. Our compliance figures are in concert with others. 22, 44 We believe our findings reflect the overall compliance of such programs in routine clinical practice, even though the compliance in a randomized controlled trial is supposed to be higher. 22 The costs of follow-up as calculated in our study were lower than estimated in the study of Norum and Olsen. 17 This is mostly explained by a lower charge for CEA analysis. 17 In addition, cost is calculated and expressed at different times and in different currencies, which make a meaningful comparison difficult. Cost analyses should also take the discount index into account and are ideally measured in generally comparable terms like cost-utility analyses, which requires a comparative study design. 45 Cost is also hard to compare with publications from other countries because of different reimbursement policy. A recent report from France reported cost figures from two different follow-up schedules. 46 The costs were fairly comparable to our figures in Table 4 . However, the numbers of examinations according to the French schedules were lower than those from the Norwegian recommendations. The uncertainty of cost figures is reflected by the wide CIs (Table 4) as they depend not only on reimbursement practice but also on the frequency of examinations performed. Thus, care should be taken when comparing cost figures alone. Finally, to decide whether these expenses are costeffective depends on what a given society is willing to pay for the potential benefits of treating recurrent CRC and how to make priorities with regard to other concurring patient groups. This decision is, beside the medicoethical issue of offering the best possible care to every single patient at any time, a matter of public discussion based on valid scientific recommendations.
The effectiveness of Norwegian guidelines in this unselected patient cohort was limited to 9%. Compliance was only moderate. Whether the identified costs are acceptable is a matter of public discussion based on valid scientific recommendations.
